[The role of cholesterol-lowering drugs in prevention of coronary heart disease].
Hypercholesterolemia is an important risk factor of coronary heart disease. Pol-MONICA study performed in 1983-84 showed that at that time 65% of Polish population had an increased blood cholesterol level. After 10 years that percentage rose up to 70 in men and 67 in women. It is the reason for concern that prescription of cholesterol-lowering drugs is still insufficient. It has been proven that 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (HMG-CoA reductase inhibitors), named statins, which are recognized as the strongest cholesterol-lowering drugs, cause a significant decrease in the rate of acute coronary episodes and total mortality in both primary and secondary prevention of coronary heart disease. Moreover, statins induce the inhibition of progression, or even regression, of atherosclerotic lesions, as demonstrated by echocardiography. The aim of therapy is to decrease blood LDL-cholesterol level to 3.0-3.5 mmol/l (115-135 mg/dl). It should be emphasized, however, that any reduction in cholesterol concentration can provide distinct clinical benefits. Therefore, it seems important to present data on the recent progress in effective treatment of hypercholesterolemia and benefits arising from this approach.